Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma

Yonsei Medical Journal

Volumn 46, Issue 1, 2005, Pages 133-140

  Cho, Dae Sung ^a   Joo, Hee Jae ^a   Oh, Dong Keun ^a   Kang, Ji Hun ^a   Kim, Young Soo ^a   Lee, Kyi Beom ^a   Kim, Se Joong ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Cyclooxygenase 2; p53; Prognosis; Renal cell carcinoma

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR VOLUME;

EID: 14944358654     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2005.46.1.133     Document Type: Article

References (29)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
2. Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 1998;15:68-76.
3. Yasunaga Y, Shin M, Miki T, Okuyama A, Aozasa K. Prognostic factors of renal cell carcinoma: a multivariate analysis. J Surg Oncol 1998;68:11-8.
4. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
5. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-40.
6. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6:4064-8.
7. Joo YE, Rew JS, Seo YH, Choi SK, Kim YJ, Park CS, et al. Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. J Clin Gastroenterol 2003;37:28-33.
8. Denkert C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, et al. Elevated expression of cyclooxgenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-87.
9. Chen YJ, Wang LS, Wang PH, Lai CR, Yen MS, Ng HT, et al. High cyclooxygenase-2 expression in cervical adenocarcinomas. Gynecol Oncol 2003;88:379-85.
10. Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
11. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-96.
12. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000;6:2424-30.
13. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190:279-86.
14. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
15. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 2003;169:2352-9.
16. Khan KN, Stanfieid KM, Trajkovic D, Knapp DW. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 2001;38:116-9.
17. Okamoto T, Hara A, Hino O. Down-regulation of cyclooxygenase-2 expression but up-regulation of cyclooxygenase-1 in renal carcinomas of the Eker (TSC2 gene mutant) rat model. Cancer Sci 2003;94:22-5.
18. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 2003;9: 1741-9.
19. Yoshimura R, Matsuyama M, Kawahito Y, Tsuchida K, Kuratsukuri K, Takemoto Y, et al. Study of cyclooxygenase-2 in renal cell carcinoma. Int J Mol Med 2004; 13:229-33.
20. Girgin C, Tarhan H, Hekimgil M, Sezer A, Gürel G. p53 mutations and other prognostic factors of renal cell carcinoma. Urol Int 2001;66:78-83.
21. Uchida T, Gao JP, Wang C, Jiang SX, Muramoto M, Satoh T, et al. Clinical significance of p53, mdm2 and bcl-2 proteins in renal cell carcinoma. Urology 2002;59: 615-20.
22. Papadopoulos I, Rudolph P, Weichert-Jacobsen K. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma. Eur Urol 1997;32:110-7.
23. Hofmockel G, Wittmann A, Dammrich J, Bassukas ID. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res 1996;16:3807-11.
24. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:992-3.
25. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
26. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
27. Hara S, Kondo Y, Matsuzawa I, Hashimoto Y, Kimura G, Akimoto M, et al. Expression of cyclooxygenase-2 in human bladder and renal cell carcinoma. Adv Exp Med Biol 2002;507:123-6.
28. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
29. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;95: 681-6.